References
- World Health Organization. Roadmap for childhood tuberculosis: towards zero deaths. Geneva: WHO, 2013. Available from: http://www.theunion.org/images/stories/news/ChildhoodTB-Roadmap_Final_1October2013.pdf
- Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis. 2006;10:259–63.
- Zar HJ, Pai M. Childhood tuberculosis – a new era. Paediatr Respir Rev. 2011;12:1–2.
- Craig SR, Adams LV, Spielberg SP, Campbell B. Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes. Soc Sci Med. 2009;69:1681–90.
- Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012;55:1088–95.
- Department of Health, South Africa. National Tuberculosis Management Guidelines, 2009.
- Lin MY, Lin SJ, Chan LC, Lu YC. Impact of food and antacids on the pharmacokinetics of antituberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14:806–18.
- Kiser JJ, Zhu R, D’Argenio DZ, Cotton MF, Bobat R, McSherry GD, et al. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. Ther Drug Monit. 2012;34:446–51.
- Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560–7.
- Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208:1464–73.
- Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, et al. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis. 2013;17:800–6.
- Donald PR, Ahmed A, Burman WJ, Cotton MF, Graham SM, Mendel C, et al. Requirements for the clinical evaluation of new anti-tuberculosis agents in children. Int J Tuberc Lung Dis. 2013;17:794–9.
- Best BM, Capparelli EV, Diep H, Rossi SS, Farrell MJ, Williams E, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immun Defic Syndr. 2011;58:385–91.
- Notterman DA, Nardi M, Saslow JG. Effect of dose formulation on isoniazid absorption in two young children. Pediatrics. 1986;77:850–2.
- Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis. 2010;10:125–32.
- Waning B, Diedrichsen E, Jambert E, Barnighausen T, Li Y, Pouw M, et al. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. BMC Pediatr. 2010;10:74.